Quantitative analysis of somatostatin receptor subtype (SSTR1–5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas

European Journal of Endocrinology - Tập 156 Số 1 - Trang 65-74 - 2007
Giselle Fernandes Taboada1, Raúl M. Luque2, Wildebranham Bastos3, Renata F.C. Guimarães1, Jorge B Marcondes4, Leila Chimelli5, Rosita Fontes6,7, Paulo J P Mata3, Paulo Niemeyer Filho3, Denise Pires de Carvalho8, Rhonda D. Kineman2, Mônica R. Gadelha6,1
1Serviços de Endocrinologia, Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil
2Section of Endocrinology and Metabolism, Department of Medicine, University of Illinois at Chicago and Jesse Brown VA Medical Center, Chicago, Illinois, USA
3Serviço de Neurocirurgia do Hospital da Santa Casa de Misericórdia do Rio de Janeiro, Pontifícia Universidade Católica, Rio de Janeiro, Brazil
4Neurocirurgia, Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil
5Anatomia Patológica, Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil
6Instituto Estadual de Diabetes e Endocrinologia Luis Capriglione, Rio de Janeiro, Brazil
7Laboratório Diagnósticos da América, Rio de Janeiro, Brazil
8Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

Tóm tắt

Objective: It is believed that the variable effectiveness of somatostatin analogs in post-surgical management of somatotropinomas and non-functioning pituitary adenomas (NFPA) may be due in part to variable expression of somatostatin receptor isoforms (SSTR1–5), within and between pituitary tumor types. Design and methods: Quantitative real-time RT-PCR was used to compare absolute mRNA copy numbers for all five SSTR isoforms in 23 somatotropinomas and 19 NFPA. Results: Somatostatin receptor subtype 5 mRNA was present at the highest level in somatotropinomas, followed by SSTR2>SSTR3≫SSTR1⋙SSTR4. In contrast, SSTR3 mRNA was present at the highest level in NFPA, followed by SSTR2, while SSTR1, SSTR4, and SSTR5 transcripts were only detectable in select tumors. Among somatotropinomas, a positive correlation was found between SSTR2 mRNA levels and the percent decrease of GH (%GH) after 3 and 6 months of therapy with octreotide long acting repeatable (LAR) (r=0.51 and r=0.66; P=0.05 and P=0.008). Also the percent decrease of IGF-I (%IGF-I) after 3 months of octreotide LAR was negatively correlated with SSTR5 and %IGF-I after 6 months of octreotide LAR was positively correlated with SSTR2. Conclusions: The present report is a large series examining SSTR mRNA levels in somatotropinomas and NFPA. These initial findings suggest that detailed knowledge of the SSTR mRNA expression profile in somatotropinomas can help to predict the hormonal response to therapy with LAR. Also, it appears that SSTR3 in NFPA may be a potential target for SSTR3 preferential or universal ligands such as pasireotide.

Từ khóa


Tài liệu tham khảo

Mortini, 2005, Neurosurgery, 56, 1222, 10.1227/01.NEU.0000159647.64275.9D

Giustina, 2000, Journal of Clinical Endocrinology & Metabolism, 85, 526, 10.1210/jc.85.2.526

Ahmed, 1999, Clinical endocrinology, 50, 561, 10.1046/j.1365-2265.1999.00760.x

Gittoes, 1999, QJM, 92, 741, 10.1093/qjmed/92.12.741

Sheaves, 1996, Clinical endocrinology, 45, 407, 10.1046/j.1365-2265.1996.8370847.x

Turner, 1999, Clinical endocrinology, 51, 281, 10.1046/j.1365-2265.1999.00865.x

Comtois, 1991, Cancer, 68, 860, 10.1002/1097-0142(19910815)68:4<860::AID-CNCR2820680431>3.0.CO;2-4

Gittoes, 1998, Clinical endocrinology, 48, 331, 10.1046/j.1365-2265.1998.00393.x

Freda, 2002, Journal of Clinical Endocrinology &amp; Metabolism, 87, 3013, 10.1210/jc.87.7.3013

Cozzi, 2003, Journal of Clinical Endocrinology &amp; Metabolism, 88, 3090, 10.1210/jc.2003-030110

2005, Journal of Clinical Endocrinology &amp; Metabolism, 90, 1856, 10.1210/jc.2004-1093

Katznelson, 1992, Journal of Clinical Endocrinology &amp; Metabolism, 75, 1318, 10.1210/jc.75.5.1318

Plockinger, 1994, Journal of Clinical Endocrinology &amp; Metabolism, 79, 1416, 10.1210/jc.79.5.1416

Hofland, 2004, Frontiers of hormone research, 32, 235, 10.1159/000079048

Patel, 1999, Frontiers in neuroendocrinology, 20, 157, 10.1006/frne.1999.0183

van der Hoek, 2005, Current pharmaceutical design, 11, 1573, 10.2174/1381612053764832

Greenman, 1994, Journal of Clinical Endocrinology &amp; Metabolism, 79, 724, 10.1210/jc.79.3.724

Corbetta, 2001, European journal of clinical investigation, 31, 208, 10.1046/j.1365-2362.2001.00786.x

Jaquet, 2000, Journal of Clinical Endocrinology &amp; Metabolism, 85, 781, 10.1210/jc.85.2.781

Park, 2004, Endocrine journal, 51, 227, 10.1507/endocrj.51.227

Saveanu, 2001, Journal of Clinical Endocrinology &amp; Metabolism, 86, 140, 10.1210/jc.86.1.140

Matrone, 2004, Neuroendocrinology, 79, 142, 10.1159/000077272

Florio, 2003, Clinical endocrinology, 59, 115, 10.1046/j.1365-2265.2003.01811.x

Florio, 1999, European Journal of Endocrinology, 141, 396, 10.1530/eje.0.1410396

Danila, 2001, Journal of Clinical Endocrinology &amp; Metabolism, 86, 2976, 10.1210/jc.86.7.2976

Nielsen, 1998, Journal of Clinical Endocrinology &amp; Metabolism, 83, 2997, 10.1210/jc.83.8.2997

Miller, 1995, Journal of Clinical Endocrinology &amp; Metabolism, 80, 1386, 10.1210/jc.80.4.1386

Panetta, 1995, Life sciences, 56, 333, 10.1016/0024-3205(94)00956-2

1996, Journal of Endocrinology, 8, 605

Nielsen, 2001, Journal of endocrinological investigation, 24, 430, 10.1007/BF03351043

Greenman, 1994, Journal of Clinical Endocrinology &amp; Metabolism, 78, 398, 10.1210/jc.78.2.398

Hofland, 2004, Journal of Clinical Endocrinology &amp; Metabolism, 89, 1577, 10.1210/jc.2003-031344

Saveanu, 2001, European Journal of Endocrinology, 145, 35, 10.1530/eje.0.1450035

Olias, 2004, Journal of neurochemistry, 89, 1057, 10.1111/j.1471-4159.2004.02402.x

Shimon, 1997, Journal of Clinical Investigation, 100, 2386, 10.1172/JCI119779

Zatelli, 2003, Journal of Clinical Endocrinology &amp; Metabolism, 88, 2797, 10.1210/jc.2002-021825

Boerlin, 2003, Journal of endocrinological investigation, 26, 14

Hannon, 2002, Journal of molecular neuroscience : MN, 18, 15, 10.1385/JMN:18:1-2:15

2002, Medline Rows With NULL issns Will Point To This, 3, 1

Raynor, 1993, Molecular Pharmacology, 43, 838

Raynor, 1993, Molecular Pharmacology, 44, 385

Ren, 2003, Journal of Clinical Endocrinology &amp; Metabolism, 88, 4239, 10.1210/jc.2003-030303

de Bruin, 1992, Journal of Clinical Endocrinology &amp; Metabolism, 75, 1310, 10.1210/jc.75.5.1310

Sharma, 1996, Molecular Endocrinology, 10, 1688, 10.1210/me.10.12.1688

Thông tin
Thông tin xuất bản

European Journal of Endocrinology

Tập 156 Số 1

65-74

Thông tin tác giả